Information Provided By:
Fly News Breaks for March 2, 2015
AMGN, LGND
Mar 2, 2015 | 09:19 EDT
After Ligand's (LGND) partner, Amgen (AMGN), announced that Kyprolis achieved the primary endpoint of PFS in a study, Roth thinks the study should establish Kyprolis' superiority over Velcade as a proteasome inhibitor for r/r multiple myeloma. The firm keeps a $116 price target and Buy rating on Ligand.
News For LGND;AMGN From the Last 2 Days
There are no results for your query LGND;AMGN
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.